ResultsIQ

ResultsIQ › Latest results › Acutaas Chemicals Limited

Acutaas Chemicals Limited Q2 FY26 results deck summary

NSE: ACUTAAS · BSE: 543349

Results deck of 17 Oct 2025, summarised by AI from the filing.

Revenue grew 24.1% year-on-year to ₹3,062 million, driven by Advanced Pharmaceutical Intermediates and stable Specialty Chemicals.

Key takeaways

  1. Q2 FY26 revenue Revenue grew 24.1% year-on-year to ₹3,062 million, driven by Advanced Pharmaceutical Intermediates and stable Specialty Chemicals.
  2. EBITDA margin EBITDA margin improved to 31.1% in Q2 FY26 from 19.8% in Q2 FY25.
  3. Risk Forward-looking statements are subject to risks and uncertainties that could cause actual outcomes to differ materially.

Original filing on BSE

Acutaas Chemicals Limited Q1 FY27 results

As filed: Revenue ₹330 cr (+59% year on year), EBITDA ₹113 cr (+122% year on year), PAT ₹75.0 cr (+70% year on year), EBITDA margin 34.3% (+966 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹422 cr, EBITDA ₹181 cr, PAT ₹137 cr, EBITDA margin 43.0%. Not scored. No result for the same quarter last year. Share price after the results: +25.2% in 29 days (Nifty 500: −0.9%).
  • Q3 FY26: Revenue ₹391 cr, EBITDA ₹154 cr, PAT ₹112 cr, EBITDA margin 39.5%. Not scored. No result for the same quarter last year. Share price after the results: +30.9% in 30 days (Nifty 500: +1.5%).
  • Q2 FY26: Revenue ₹305 cr, EBITDA ₹97.0 cr, PAT ₹73.0 cr, EBITDA margin 31.8%. Not scored. No result for the same quarter last year. Share price after the results: +10.2% in 28 days (Nifty 500: +1.2%).
  • Q1 FY26: Revenue ₹206 cr, EBITDA ₹51.0 cr, PAT ₹45.0 cr, EBITDA margin 24.8%. Not scored. No result for the same quarter last year. Share price after the results: +20.5% in 30 days (Nifty 500: −2.4%).

Past price moves after results do not indicate future moves. Not a recommendation.

Acutaas Chemicals Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.